智通财经APP讯，巨子生物(02367)公布2025年业绩，收入约55.185亿元，同比减少0.4%;毛利约44.334亿元，同比减少2.5%;归属于母公司持有者盈利约19.15亿元，同比减少7.2%;经调整净利润约19.6亿元，同比减少8.9%;每股基本盈利1.83元，建议派发末期股息每股0.5390元及特别股息每股0.6714元。
公告称，整体收入基本持平，主要受专业皮肤护理产品的销售变动影响，其中功效性护肤品收入增加得益于公司持续加强在全渠道的营销活动，以及明星单品可复美焦点面霜的持续放量和可丽金大膜王3.0迭代升级后的成功上市;医用敷料收入有所下降，主要系公司为维护产品价格体系，主动加强渠道销售管控，对短期收入规模带来一定影响。毛利减少主要由于销售收入的减少和销售成本的增加。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.